Economic analysis of risk and uncertainty induced by health shocks: A review and extension

Handbook of the Economics of Risk and Uncertainty

Volumn 1, Issue , 2014, Pages 453-491

  Philipson, Tomas J ^a   Zanjani, George ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Health care spending; Health human capital; Health insurance; Health risk; Medical innovation

Indexed keywords

EID: 84968571709     PISSN: 22117547     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53685-3.00008-8     Document Type: Conference Paper

References (99)

1. Abaluck, J., Gruber, J., 2011. Choice inconsistencies among the elderly: Evidence from plan choice in the medicare part D program. American Economic Review 101, 1180-1210.
2. Abbring, J.H., Chiappori, P.A., Heckman, J.J., Pinquet, J., 2003. Adverse selection and moral hazard: can dynamic data help to distinguish?. Journal of the European Economic Association 1, 512-521.
3. Adams, C.P., Brantner, V.V., 2006. Estimating the cost of new drug development: is it really $802 million?. Health Affairs 25, 420-428.
4. Akerlof, G.A., 1970. The market for "lemons": quality uncertainty and the market mechanism. Quarterly Journal of Economics 84, 488-500.
5. Altman, D., Cutler, D.M., Zeckhauser, R.J., 1998. Adverse selection and adverse retention. American Economic Review 88, 122-136.
6. Arrow, K.J., 1963. Uncertainty and the welfare economics of medical care. American Economic Review 53, 942-973.
7. Baily, M.N., 1972. Research and development costs and returns: The U.S. pharmaceutical industry. Journal of Political Economy 80, 70-85.
8. Bakke, O.M., Wardell, W.M., Lasagna, L., 1984. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clinical Pharmacology & Therapeutics 35, 559-567.
9. Bakke, O.M., Manocchia, M., de Abajo, F., Kaitin, K.I., Lasagna, L., 1995. Drug safety discontinuations in the United Kingdon, the United States, and Spain from 1974 through 1993: A regulatory perspective. Clinical Pharmacology & Therapeutics 58, 108-117.
10. Berndt, E.R., Gottschalk, A.H.B., Philipson, T.J., Strobeck, M.W., 2005a. Assessing the impacts of the prescription drug user fee acts (PDUFA) on the FDA approval process. Forum for Health Economics & Policy 8. Article 2.
11. Berndt, Ernst.R., Gottschalk, A.H.B., Philipson, T.J., Strobeck, M.W., 2005b. Industry funding of the FDA: Effects of PDUFA on approval times and withdrawal rates. Nature Reviews Drug Discovery 4, 545-554.
12. Cardon, J.H., Hendel, I., 2001. Asymmetric information in health insurance: Evidence from the national medical expenditure survey. RAND Journal of Economics 32, 408-427.
13. Carpenter, D., Chernew, M., Smith, D.G., Fendrick, A.M., 2003. Approval times for new drugs: does the source of funding for FDA staff matter?. Health Affairs, http://dx.doi.org/10.1377/hlthaff.w3.618.
14. Carpenter, D., Zucker, E.J., Avorn, J., 2008a. Drug-review deadlines and safety problems. New England Journal of Medicine 358, 1354-1361.
15. Carpenter, D., Zucker, E.J., Avorn, J., 2008b. Drug-review deadlines and safety problems: Author's reply. New England Journal of Medicine 359, 96-98.
16. Cawley, J., Philipson, T.J., 1999. An empirical examination of information barriers to trade in insurance. American Economic Review 89, 827-846.
17. Center for Drug Evaluation and Research (CDER), 2004. 2003 Report to the Nation: Improving Public Health through Human Drugs. US Dept. of Health and Human Services, Food and Drug Administration.
18. Chandra, A., Gruber, J., McKnight, R., 2010. Patient cost-sharing and hospitalization offsets in the elderly. American Economic Review 100, 193-213.
19. Chernew, M.E., Fendrick, A.M., 2008. Value and increased cost sharing in the American health care system. Health Services Research 43, 251-257.
20. Chernew, M.E., Newhouse, J.P., 2012. Health care spending growth. In: Pauly, M.V., McGuire, T.G., Barros, P.P. (Eds.), Handbook of Health Care Economic. Elsevier, Amsterdam, pp. 1-44.
21. Chiappori, P.-A., Salanié, B., 2000. Testing for asymmetric information in insurance markets. Journal of Political Economy 108, 56-78.
22. Clemens, J.P., 2013. The Effect of US Health Insurance Expansions on Medical Innovation. SIEPR Discussion Paper No. 11-016. Available at SSRN: or http://dx.doi.org/10.2139/ssrn.2101246.
23. Cohen, A., 2005. Asymmetric information and learning in the automobile insurance market. Review of Economics and Statistics 87, 197-207.
24. Cohen, A., Siegelman, P., 2010. Testing for adverse selection in insurance markets. Journal of Risk and Insurance 77, 39-84.
25. Congressional Budget Office (CBO), January 2008. Technological Change and the Growth of Health Care Spending.
26. Connolly, M.P., Griesinger, G., Ledger, W., Postma, M.J., 2009. The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: A price-elasticity of demand assessment. Human Reproduction 24, 2796-2800.
27. Cook, P.J., Graham, D.A., 1977. The demand for insurance and protection: The case of irreplaceable commodities. Quarterly Journal of Economics 91, 143-156.
28. Cullen, R., 1983. Pharmaceuticals inter-country diffusion. Managerial & Decision Economics 4, 73-82.
29. Cutler, D.M., Reber, S.J., 1998. Paying for health insurance: The trade-off between competition and adverse selection. Quarterly Journal of Economics 113, 433-466.
30. Danzon, P.M., Pauly, M.V., 2002. Health insurance and the growth in pharmaceutical expenditures. Journal of Law and Economics 45, 587-613.
31. Dimasi, J.A., Grabowski, H.G., 2012. R&D costs and the returns to new drug development: A review of the evidence. In: Danzon, P.M., Nicholson, S. (Eds.), The Oxford Handbook of the Economics of the Pharmaceutical Industry. Oxford University Press, New York, pp. 21-46.
32. Dimasi, J.A., Bryant, N.R., Lasagna, L., 1991. New drug development in the united-states from 1963 to 1990. Clinical Pharmacology & Therapeutics 50, 471-486.
33. Dimasi, J.A., Hansen, R.W., Grabowski, H.G., 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22, 151-185.
34. Dionne, G., 1982. Moral hazard and state-dependent utility function. Journal of Risk and Insurance 49, 405-422.
35. Dionne, G., Gouriéroux, C., Vanasse, C., 2001. Testing for evidence of adverse selection in the automobile insurance market: A comment. Journal of Political Economy 109, 444-453.
36. Dranove, D., Meltzer, D., 1994. Do important drugs reach the market sooner?. RAND Journal of Economics 25, 402-423.
37. Fang, H., Keane, M.P., Silverman, D., 2008. Sources of advantageous selection: Evidence from the Medigap insurance market. Journal of Political Economy 116, 303-350.
38. Finkelstein, A., 2004. Static and dynamic effects of health policy: Evidence from the vaccine industry. Quarterly Journal of Economics 119, 527-564.
39. Finkelstein, A., 2007. The aggregate effects of health insurance: Evidence from the introduction of medicare. Quarterly Journal of Economics 122, 1-37.
40. Finkelstein, A., McGarry, K., 2006. Multiple dimensions of private information: Evidence from the long term care insurance market. American Economic Review 96, 938-958.
41. Finkelstein, A., Poterba, J., 2002. Selection effects in the United Kingdom individual annuities market. Economic Journal 112, 28-50.
42. Finkelstein, A., Poterba, J., 2004. Adverse selection in insurance markets: policyholder evidence from the U.K. annuity market. Journal of Political Economy 112, 183-208.
43. Frank, R., 2007. Behavior economics and health economics. In: Diamond, P., Vartiainen, H. (Eds.), Behavior Economics and its Applications. Princeton University Press, Princeton, NJ.
44. Frank, R., Lamiraud, K., 2009. Choice, price competition, and complexity in markets for health insurance. Journal of Economic Behavior and Organization 71, 550-562.
45. Gaynor, M., Rebitzer, J.B., Taylor, L.J., 2004. Physician incentives in health maintenance organizations. Journal of Political Economy 112, 915-931.
46. General Accounting Office (GAO), 2002. Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities.
47. Goldman, D., Joyce, G., Zheng, Y., 2007a. Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. Journal of the American Medical Association 298, 61-69.
48. Goldman, D., Philipson, T., 2007b. Integrated insurance design with multiple medical technologies. American Economic Review 97, 427-432.
49. Grabowski, H.G., Vernon, J.M., Thomas, L.G., 1978. Estimating the effect of regulation on innovation: An international comparative analysis of the pharmaceutical industry. Journal of Law and Economics 21, 133-163.
50. Grace, M.F., Klein, R.W., Kleindorfer, P.R., 2004. Homeowners insurance with bundled catastrophe coverage. Journal of Risk and Insurance 71, 351-379.
51. Gruber, J., Poterba, J., 1994. Tax incentives and the decision to purchase health insurance: Evidence from the self-employed. Quarterly Journal of Economics 109, 701-733.
52. Hansen, R.W., 1979. The pharmaceutical development process: Estimates of current development costs and times and the effects of regulatory changes. In: Chien, R.I. (Ed.), Issues in Pharmaceutical Economics. Lexington Books, Lexington, MA, pp. 151-187.
53. He, D., 2009. The life insurance market: Asymmetric information revisited. Journal of Public Economics 93, 1090-1097.
54. Hendel, I., Lizzeri, A., 2003. The role of commitment in dynamic contracts: Evidence from life insurance. Quarterly Journal of Economics 188, 299-327.
55. Himmelstein, D.U., Thorne, D., Warren, E., Woolhandler, S., 2009. Medical bankruptcy in the United States, 2007: Results from a national study. The American Journal of Medicine, 741-746.
56. Hult, K., Philipson, T., 2012. Health Care Reforms and the Value of Future Public Liabilities. NBER Working Paper 18571.
57. Hutt, P.B., Merrill, R.A., Grossman, L.A., 2007. Food and drug law: cases and materials, third ed. Foundation Press, NY.
58. Jensen, E.J., 1987. Research expenditures and the discovery of new drugs. Journal of Industrial Economics 36, 83-95.
59. Kaitin, K.I., DiCerbo, P.A., Lasagna, L., 1991. The new drug approvals of 1987, 1988, and 1989: Trends in drug development. The Journal of Clinical Pharmacology 31, 116-122.
60. Keeler, E.B., Rolph, J.E., 1988. The demand for episodes of treatment in the health insurance experiment. Journal of Health Economics, 337-367.
61. Kniesner, T.J., Viscusi, W.K., Woock, C., Ziliak, J.P., 2012. The value of a statistical life: Evidence from panel data. Review of Economics and Statistics 94, 74-87.
62. Koijen, R., Philipson, T., Uhlig, H., 2012. Financial Health Economics. Working Paper, Department of Economics, University of Chicago.
63. Kondo, M., Hoshi, S., Okubo, I., 2009. Does subsidy work? Price elasticity of demand for influenza vaccination among elderly in Japan. Health Policy 91, 269-276.
64. Kremslehner, D., Muermann, A., 2013. Asymmetric Information in Automobile Insurance: New Evidence from Telematic Data. Working Paper. Available at SSRN: or http://dx.doi.org/10.2139/ssrn.2048478.
65. Krueger, A.B., Kuziemko, I., 2013. The demand for health insurance among uninsured Americans: Results of a survey experiment and implications for policy. Journal of Health Economics 32, 780-793.
66. Levy, H., Meltzer, D., 2008. The impact of health insurance on health. Annual Review of Public Health 29, 399-409.
67. Liebman, J., Zeckhauser, R., 2008. Simple Humans, Complex Insurance, Subtle Subsidies. NBER Working Paper 14330.
68. Manning, W.G., Newhouse, J.P., Duan, N., Keeler, E.B., Leibowitz, A., Marquis, M.S., 1987. Health insurance and the demand for medical care: Evidence from a randomized experiment. American Economic Review 77, 251-277.
69. May, M.S., Wardell, W.M., Lasagna, L., 1983. New drug development during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958-1979. Clinical Pharmacology and Therapeutics 33, 691-700.
70. McCarthy, D., Mitchell, O.S., 2010. International adverse selection in life insurance and annuities. In: Tuljapurkar, S., Ogawa, N., Gauthier, A.H. (Eds.), Ageing in Advanced Industrial States: Riding the Age Waves, vol. 3. Springer, pp. 119-135.
71. McFadden, D., 2006. Free markets and fettered consumers. American Economic Review 96, 5-29.
72. McGuire, T.G., 2012. Demand for health insurance. In: Pauly, M.V., McGuire, T.G., Barros, P.P. (Eds.), Handbook of Health Economics, vol. 2. Elsevier.
73. Mulligan, C., Philipson, T.J., 2004. Insurance Market Participation under Symmetric Information. Working Paper.
74. Mund, V.F., 1970. The return on investment of the innovative pharmaceutical firm. In: Cooper, J.D. (Ed.), The Economics of Drug Innovation. American University, Washington, DC, pp. 125-138.
75. Murphy, K.M., Topel, R.H., 2006. The value of health and longevity. Journal of Political Economy 114, 871-904.
76. Newhouse, J., 1992. Medical care costs: how much welfare loss?. Journal of Economic Perspectives 6, 3-21.
77. Nyman, J.A., 1999. The value of health insurance: The access motive. Journal of Health Economics 18, 141-152.
78. Olson, M.K., 2004. Explaining reductions in FDA drug review times: PDUFA matters. Health Affairs, http://dx.doi.org/10.1377/hlthaff.w4.s1.
79. Oster, E., Shoulson, I., Quaid, K.A., Dorsey, E.R., 2010. Genetic adverse selection: Evidence from long- Term care insurance and Huntington's disease. Journal of Public Economics 94, 1041-1050.
80. Pauly, M.V., 1968. The economics of moral hazard: comment. American Economic Review 58, 531-537.
81. Pauly, M.V., 1990. The rational nonpurchase of long term care insurance. Journal of Political Economy 98, 153-168.
82. Peltzman, S., 1973. An evaluation of consumer safety protection legislation: The 1962 drug amendments. Journal of Political Economy 81, 1049-1091.
83. Philipson, T.J., Berndt, E.R., Gottschalk, A.H.B., Sun, E., 2008. Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts. Journal of Public Economics, 92, 1306-1325.
84. Philipson, T.J., Sun, E., Goldman, D., 2009. The Effects of Product Liability Exemption in the Presence of the FDA. NBER Working Paper 15603.
85. Philipson, T., Sun, E., Sun, A. Jena., Goldman, D., 2009. A Re-examination of the Costs of Medical R&D. Working Paper.
86. Richaudeau, D., 1999. Automobile insurance contracts and risk of accident: An empirical test using French individual data. The Geneva Papers on Risk and Insurance - Theory 24, 97-114.
87. Rothschild, M., Stiglitz, J., 1976. Equilibrium in competitive insurance markets: An essay on the economics of imperfect information. Quarterly Journal of Economics 90, 629-649.
88. Saito, K., 2006. Testing for asymmetric information in the automobile insurance market under rate regulation. Journal of Risk and Insurance 73, 335-356.
89. Sarett, L.H., 1974. FDA regulations and their influence on future research and development. Research Management 17, 18-20.
90. Strombom, B.A., Buchmueller, T.C., Feldstein, P.J., 2002. Switching costs, price sensitivity and health plan choice. Journal of Health Economics 21, 89-116.
91. Thomas, L.G., 1990. Regulaton and firm size: FDA impacts on innovation. RAND Journal of Economics 21, 497-517.
92. Viscusi, W.K., Aldy, J.E., 2003. The value of a statistical life: A critical review of market estimates throughout the world. Journal of Risk and Uncertainty 27, 5-76.
93. Wardell, W., 1973. Introduction of new therapeutic drugs in the United States and Great Britain: An international comparison. Clinical Pharmacology and Therapeutics 14, 773-790.
94. Weisbrod, B., 1991. The health care quadrilemma: An essay on technological change, insurance, quality of care, and cost containment. Journal of Economic Literature 29, 523-552.
95. Wiggins, S.N., 1981. Product quality regulation and new drug introductions: some new evidence from the 1970s. Review of Economics and Statistics 63, 615-619.
96. Wiggins, S.N., 1983. The impact of regulation on pharmaceutical research expenditures: A dynamic approach. Economic Inquiry 21, 115-128.
97. Wolfe, J.R., Goddeeris, J.H., 1991. Adverse selection, moral hazard, and wealth effects in the Medigap insurance market. Journal of Health Economics 10, 433-459.
98. Zeckhauser, R.J., 1970. Medical insurance: A case study of the tradeoff between risk spreading and appropriate incentives. Journal of Economic Theory 2, 10-26.
99. Zeckhauser, R.J., 1973. Coverage for Catastrophic illness. Public Policy 21, 149-172.